Wild-type IDH1 inhibition enhances chemotherapy response in melanoma
Authors:
Open Access
- 24 September 2022
- journal article
- research article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 41 (1) , 1-18
Abstract
Background: Alternative treatment strategies in melanoma beyond immunotherapy and mutation-targeted therapy are urgently needed. Wild-type isocitrate dehydrogenase 1 (wtIDH1) has recently been implicated as a metabolic dependency in cancer. The enzyme protects cancer cells under metabolic stress, including nutrient limited conditions in the tumor microenvironment. Specifically, IDH1 generates NADPH to maintain redox homeostasis and produces α-ketoglutarate to support mitochondrial function through anaplerosis. Herein, the role of wtIDH1 in melanoma is further explored. Methods: The expression of wtIDH1 was determined by qRT-PCR, and Western blot in melanoma cell lines and the effect of wtIDH1 on metabolic reprogramming in melanoma was interrogated by LC-MS. The impact of wtIDH1 inhibition alone and in combination with chemotherapy was determined in cell culture and mouse melanoma models. Results: Melanoma patients express higher levels of the wtIDH1 enzyme compared to normal skin tissue, and elevated wtIDH1 expression portends poor patient survival. Knockdown of IDH1 by RNA interference inhibited cell proliferation and migration under low nutrient levels. Suppression of IDH1 expression in melanoma also decreased NADPH and glutathione levels, resulting in increased reactive oxygen species. An FDA-approved inhibitor of mutant IDH1, ivosidenib (AG-120), exhibited potent anti-wtIDH1 properties under low magnesium and nutrient levels, reflective of the tumor microenvironment in natura. Thus, similar findings were replicated in murine models of melanoma. In light of the impact of wtIDH1 inhibition on oxidative stress, enzyme blockade was synergistic with conventional anti-melanoma chemotherapy in pre-clinical models. Conclusions: These results demonstrate the clinical potential of wtIDH1 inhibition as a novel and readily available combination treatment strategy for patients with advanced and refractory melanoma. Graphical Schematic shows increased wild-type IDH1 expression and activity as an adaptive response to metabolic stress induced by chemotherapy.Keywords
All Related Versions
Funding Information
- American Cancer Society (MRSG-14-019-01-CDD, 134170-MBG-19-174-01-MBG)
- NCI (R37CA227865-01A1)
- Case Comprehensive Cancer Center, Case Western Reserve University (5P50CA150964-0, P30CA043703)
This publication has 61 references indexed in Scilit:
- A positive/negative ion–switching, targeted mass spectrometry–based metabolomics platform for bodily fluids, cells, and fresh and fixed tissueNature Protocols, 2012
- Reductive carboxylation supports growth in tumour cells with defective mitochondriaNature, 2011
- Cancer statistics, 2011CA: A Cancer Journal for Clinicians, 2011
- Glycolytic Phenotype and AMP Kinase Modify the Pathologic Response of Tumor Xenografts to VEGF NeutralizationCancer Research, 2011
- Choosing between glycolysis and oxidative phosphorylation: A tumor's dilemma?Biochimica et Biophysica Acta (BBA) - Bioenergetics, 2011
- Temozolomide for the Treatment of Metastatic Melanoma: A Systematic ReviewThe Oncologist, 2007
- Temozolomide in Combination With Interferon-Alfa Versus Temozolomide Alone in Patients With Advanced Metastatic Melanoma: A Randomized, Phase III, Multicenter Study from the Dermatologic Cooperative Oncology GroupJournal of Clinical Oncology, 2005
- Management of Cutaneous MelanomaNew England Journal of Medicine, 2004
- Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?European Journal of Cancer, 2004
- The Effect of Vitamin E and Beta Carotene on the Incidence of Lung Cancer and Other Cancers in Male SmokersNew England Journal of Medicine, 1994